Paper Details

  1. Home
  2. Paper Details

Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.

Author: DeesSundee, JasminJean-Francois, MercierIsabelle, PontiggiaLaura

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the potential of pimozide as a STAT3 inhibitor for triple-negative breast cancer (TNBC). Pimozide significantly reduced invasion and migration of TNBC cells, and this effect was predicted by STAT3 phosphorylation on tyrosine residue 705 (Tyr705). These findings suggest that phosphorylated STAT3 (Tyr705) could be a novel biomarker of response to guide pimozide therapy.
Paper Details　
Original Abstract of the Article :
Triple-negative breast cancer (TNBC) displays an aggressive clinical course, heightened metastatic potential, and is linked to poor survival rates. Through its lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), this subt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515519/

データ提供：米国国立医学図書館（NLM）

A New Compass for TNBC Treatment: Phosphorylated STAT3 as a Biomarker

This research delves into the complex and often challenging world of triple-negative breast cancer (TNBC), a subtype of breast cancer known for its aggressive nature and resistance to traditional therapies. The study explores the potential of STAT3, a key signaling molecule, as a biomarker for response to pimozide, a drug typically used for mental health conditions. Through meticulous investigation and analysis, the researchers seek to identify potential therapeutic targets and biomarkers that could guide treatment decisions for TNBC patients.

A New Path Through the Desert: STAT3 as a Biomarker for TNBC

This research offers a promising avenue for navigating the challenging terrain of TNBC treatment. The study highlights the potential of phosphorylated STAT3 as a biomarker for predicting response to pimozide therapy. This discovery opens up new possibilities for personalized medicine, enabling healthcare professionals to tailor treatment strategies based on individual patient characteristics.

A Beacon of Hope: STAT3 and the Promise of Personalized TNBC Treatment

This research provides a glimmer of hope for those battling TNBC. Just as a desert traveler relies on a beacon to guide their way, healthcare professionals may soon be able to use phosphorylated STAT3 as a beacon to guide treatment decisions for TNBC patients. This study represents a significant step forward in the quest for personalized therapies for this aggressive form of cancer.

Dr. Camel's Conclusion

This research underscores the potential of STAT3 as a biomarker for predicting response to pimozide therapy in TNBC. This discovery opens up new possibilities for personalized medicine, enabling healthcare professionals to tailor treatment strategies based on individual patient characteristics. As we continue to navigate the vast desert of TNBC research, this study offers a valuable roadmap for developing more effective and targeted therapies for this challenging disease.

Date :
  1. Date Completed 2021-07-05
  2. Date Revised 2021-07-05
Further Info :

Pubmed ID

32164483

DOI: Digital Object Identifier

PMC7515519

Related Literature

Article Analysis
・Side Effects of pimozide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.